In the Claims

Please cancel claims 3, 10, and 12-15, without prejudice.

Please substitute the following claims:

Claim 1 (amended):

B4 1. A method for treating or preventing infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT) and another nucleoside analog, and wherein said feline animal receives bone marrow transplantation after total body irradiation.

Claim 4 (amended):

B2 4. The method according to claim 1, wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.

Claim 5 (amended):

5. A method for treating or preventing infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT), another nucleoside analog and an inhibitor of a retroviral protease, and wherein said feline animal receives bone marrow transplantation after total body irradiation.

Claim 8 (amended):

B3 8. The method according to claim 5, wherein said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in Figure 4.

Claim 11 (amended):

B4 11. The method according to claim 5, wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.

Please add the following new claims 16-23:

16. The method according to claim 1, wherein said azidothymidine or said another nucleoside analog is administered as an oral or nasal formulation.

B5

17. The method according to claim 1, wherein said azidothymidine or said nucleoside analog is administered by intravenous, intramuscular, or subcutaneous injection.

18. The method according to claim 1, wherein said azidothymidine or said nucleoside analog is administered in a dosage form selected from the group consisting of tablet, pill, powder, liquid solution or suspension, liposome, suppository, injectable, and infusible solution.

19. The method according to claim 1, wherein said FIV is a strain of FIV selected from the group consisting of FIV_{Pet}, FIV_{Dix}, FIV_{UK-8}, FIV_{Bang}, FIV_{Aom1}, FIV_{Aom2}, and FIV_{Shi}.

20. The method according to claim 5, wherein said azidothymidine, said another nucleoside analog, or said retroviral protease inhibitor is administered as an oral or nasal formulation.

21. The method according to claim 5, wherein said azidothymidine, said another nucleoside analog, or said retroviral protease inhibitor is administered by intravenous, intramuscular, or subcutaneous injection.

22. The method according to claim 5, wherein said azidothymidine, said another nucleoside analog, or said retroviral protease inhibitor is administered in a dosage form selected from the group consisting of tablet, pill, powder, liquid solution or suspension, liposome, suppository, injectable, and infusible solution.

23. The method according to claim 5, wherein said FIV is a strain of FIV selected from the group consisting of FIV_{Pet}, FIV_{Dix}, FIV_{UK-8}, FIV_{Bang}, FIV_{Aom1}, FIV_{Aom2}, and FIV_{Shi}.